Behavioral Toxicity Revisited: Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment

Giovanni A. Fava, Fiammetta Cosci, Emanuela Offidani, Jenny Guidi

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

In 1968, DiMascio and Shader provided a conceptual framework for behavioral toxicity of psychotropic drugs (ie, the pharmacological actions of a drug that, within the dose range in which it has been found to possess clinical utility, may produce alterations in mood, perceptual, cognitive, and psychomotor functions that limit the capacity of the individual or constitute a hazard to one's well-being). A drug effect such as sedation or motor stimulation may be considered adverse for one patient and yet therapeutic and desired for another patient; within the same patient, it may be of value at one stage of one's illness and adverse at a later stage. The concept of behavioral toxicity encompasses adverse events that may be limited to the period of drug administration and/or persist long after their discontinuation. These latter phenomena can be subsumed under the rubric of iatrogenic comorbidity. Behavioral toxicity may ensue with any type of medical drug. Examples related to antidepressant drug use (onset of suicidality and aggression, switching from unipolar to bipolar course, withdrawal phenomena upon discontinuation, postwithdrawal persistent disorders) are discussed. Consideration of potential vulnerability to adverse events including behavioral toxicity should be placed in the context of the benefits that treatment may entail.

Original languageEnglish (US)
Pages (from-to)550-553
Number of pages4
JournalJournal of Clinical Psychopharmacology
Volume36
Issue number6
DOIs
StatePublished - Dec 1 2016

Fingerprint

Psychiatry
Comorbidity
Pharmaceutical Preparations
Psychotropic Drugs
Therapeutics
Aggression
Cognition
Antidepressive Agents
Pharmacology

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Fava, Giovanni A. ; Cosci, Fiammetta ; Offidani, Emanuela ; Guidi, Jenny. / Behavioral Toxicity Revisited : Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment. In: Journal of Clinical Psychopharmacology. 2016 ; Vol. 36, No. 6. pp. 550-553.
@article{a7b3b0c380ff4bebb749c8da35085cdf,
title = "Behavioral Toxicity Revisited: Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment",
abstract = "In 1968, DiMascio and Shader provided a conceptual framework for behavioral toxicity of psychotropic drugs (ie, the pharmacological actions of a drug that, within the dose range in which it has been found to possess clinical utility, may produce alterations in mood, perceptual, cognitive, and psychomotor functions that limit the capacity of the individual or constitute a hazard to one's well-being). A drug effect such as sedation or motor stimulation may be considered adverse for one patient and yet therapeutic and desired for another patient; within the same patient, it may be of value at one stage of one's illness and adverse at a later stage. The concept of behavioral toxicity encompasses adverse events that may be limited to the period of drug administration and/or persist long after their discontinuation. These latter phenomena can be subsumed under the rubric of iatrogenic comorbidity. Behavioral toxicity may ensue with any type of medical drug. Examples related to antidepressant drug use (onset of suicidality and aggression, switching from unipolar to bipolar course, withdrawal phenomena upon discontinuation, postwithdrawal persistent disorders) are discussed. Consideration of potential vulnerability to adverse events including behavioral toxicity should be placed in the context of the benefits that treatment may entail.",
author = "Fava, {Giovanni A.} and Fiammetta Cosci and Emanuela Offidani and Jenny Guidi",
year = "2016",
month = "12",
day = "1",
doi = "10.1097/JCP.0000000000000570",
language = "English (US)",
volume = "36",
pages = "550--553",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Behavioral Toxicity Revisited : Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment. / Fava, Giovanni A.; Cosci, Fiammetta; Offidani, Emanuela; Guidi, Jenny.

In: Journal of Clinical Psychopharmacology, Vol. 36, No. 6, 01.12.2016, p. 550-553.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Behavioral Toxicity Revisited

T2 - Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment

AU - Fava, Giovanni A.

AU - Cosci, Fiammetta

AU - Offidani, Emanuela

AU - Guidi, Jenny

PY - 2016/12/1

Y1 - 2016/12/1

N2 - In 1968, DiMascio and Shader provided a conceptual framework for behavioral toxicity of psychotropic drugs (ie, the pharmacological actions of a drug that, within the dose range in which it has been found to possess clinical utility, may produce alterations in mood, perceptual, cognitive, and psychomotor functions that limit the capacity of the individual or constitute a hazard to one's well-being). A drug effect such as sedation or motor stimulation may be considered adverse for one patient and yet therapeutic and desired for another patient; within the same patient, it may be of value at one stage of one's illness and adverse at a later stage. The concept of behavioral toxicity encompasses adverse events that may be limited to the period of drug administration and/or persist long after their discontinuation. These latter phenomena can be subsumed under the rubric of iatrogenic comorbidity. Behavioral toxicity may ensue with any type of medical drug. Examples related to antidepressant drug use (onset of suicidality and aggression, switching from unipolar to bipolar course, withdrawal phenomena upon discontinuation, postwithdrawal persistent disorders) are discussed. Consideration of potential vulnerability to adverse events including behavioral toxicity should be placed in the context of the benefits that treatment may entail.

AB - In 1968, DiMascio and Shader provided a conceptual framework for behavioral toxicity of psychotropic drugs (ie, the pharmacological actions of a drug that, within the dose range in which it has been found to possess clinical utility, may produce alterations in mood, perceptual, cognitive, and psychomotor functions that limit the capacity of the individual or constitute a hazard to one's well-being). A drug effect such as sedation or motor stimulation may be considered adverse for one patient and yet therapeutic and desired for another patient; within the same patient, it may be of value at one stage of one's illness and adverse at a later stage. The concept of behavioral toxicity encompasses adverse events that may be limited to the period of drug administration and/or persist long after their discontinuation. These latter phenomena can be subsumed under the rubric of iatrogenic comorbidity. Behavioral toxicity may ensue with any type of medical drug. Examples related to antidepressant drug use (onset of suicidality and aggression, switching from unipolar to bipolar course, withdrawal phenomena upon discontinuation, postwithdrawal persistent disorders) are discussed. Consideration of potential vulnerability to adverse events including behavioral toxicity should be placed in the context of the benefits that treatment may entail.

UR - http://www.scopus.com/inward/record.url?scp=84987864044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987864044&partnerID=8YFLogxK

U2 - 10.1097/JCP.0000000000000570

DO - 10.1097/JCP.0000000000000570

M3 - Review article

C2 - 27631576

AN - SCOPUS:84987864044

VL - 36

SP - 550

EP - 553

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 6

ER -